Transient neuroprotection by SRY upregulation in dopamine cells following injury in males

Endocrinology

Volumn 155, Issue 7, 2014, Pages 2602-2612

  Czech, Daniel P ^a,b   Lee, Joohyung ^a   Correia, Jeanne ^a   Loke, Hannah ^a   Möller, Eva K ^a   Harley, Vincent R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANISOMYCIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 GAMMA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDOPAMINE; PUMA PROTEIN; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR GATA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL DAMAGE; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RAT; SRY GENE; UPREGULATION; Y CHROMOSOME;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BENZOQUINONES; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; DOPAMINERGIC NEURONS; GATA TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN PEROXIDE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OXIDOPAMINE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PC12 CELLS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RATS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SEX-DETERMINING REGION Y PROTEIN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84903288856     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-2158     Document Type: Article

References (54)

1. Cahill L. Why sex matters for neuroscience. Nat Rev Neurosci. 2006;7:477-484. (Pubitemid 44012287)
2. Bao AM, Swaab DF. Sex differences in the brain, behavior, and neuropsychiatric disorders. Neuroscientist. 2010;16:550-565.
3. Timmons S. Akt signal transduction dysfunction in Parkinson's disease. Horm Behav. 2009;50:539-549.
4. Braak H. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517-536.
5. Vaughan R, Foster J. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013;34:489-496.
6. Arnold AP, Burgoyn PS. Are XX and XY brain cells intrinsically different? Trends Endocrinol Metab. 2004;15(1), 6-11. (Pubitemid 38198093)
7. Czech DP, Lee J, Sim H, Parish CL, Vilain E, Harley VR. The human testis-determining factor SRY localizes in midbrain dopamine neurons and regulates multiple components of catecholamine synthesis and metabolism. J Neurochem. 2012;122:260-271.
8. Dewing P, Chiang CW, Sinchak K, et al. Direct regulation of adult brain function by the male-specific factor SRY. Curr Biol. 2006;16:415-420. (Pubitemid 43259353)
9. Gillies GE, McArthur S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev. 2010;62:155-198.
10. Bourque M, Dluzen DE, Di Paolo T. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Front Neuroendocrinol. 2012;33:169-178.
11. Dluzen DE. Unconventional effects of estrogen uncovered. Trends Pharmacol Sci. 2005;26:485-487. (Pubitemid 41338557)
12. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov Disord. 1986;1:85-87.
13. Sandyk R. Estrogens and the pathophysiology of Parkinson's disease. Int J Neurosci. 1989;45:119-122.
14. Benedetti MD, Maraganore DM, Bower JH, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord. 2001;16:830-837. (Pubitemid 36041184)
15. Strijks E, Kremer JA, Horstink MW. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin Neuropharmacol. 1999;22:93-97.
16. Arnold AP. Sex chromosomes and brain gender. Nat Rev Neurosci. 2004;5:701-708. (Pubitemid 39150141)
17. Carruth LL, Reisert I, Arnold AP. Sex chromosome genes directly affect brain sexual differentiation. Nat Neurosci. 2002;5:933-934.
18. Beyer C, Eusterschulte B, Pilgrim C, Reisert I. Sex steroids do not alter sex differences in tyrosine hydroxylase activity of dopaminergic neurons in vitro. Cell Tissue Res. 1992;270:547-552.
19. Lee J, Harley V. The male fight-flight response: A result of SRY regulation of catecholamines? Bioessays. 2012;34:454-457.
20. Beyer C, Pilgrim C, Reisert I. Dopamine content and metabolism in mesencephalic and diencephalic cell cultures: sex differences and effects of sex steroids. J Neurosci. 1991;11:1325-1333.
21. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, et al. Effects of gender on nigral gene expression and parkinsons disease. Neurobiol Dis. 2007;26:606-614. (Pubitemid 46756328)
22. Sekido R, Lovell-Badge R. Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer. Nature. 2008;453:930-934. (Pubitemid 351832560)
23. Mayer A, Lahr G, Swaab DF, Pilgrim C, Reisert I. The Y-chromosomal genes SRY and ZFY are transcribed in adult human brain. Neurogenetics. 1998;1:281-288. (Pubitemid 128685086)
24. Milsted A, Serova L, Sabban EL, Dunphy G, Turner ME, Ely DL. Regulation of tyrosine hydroxylase gene transcription by Sry. Neurosci Lett. 2004;369:203-207. (Pubitemid 39298909)
25. Wu J, Chen K, li Y, Lau Y, Shih J. Regulation of monoamine oxidase Aby the SRY gene on the Y chromosome. FASEB J. 2009;23:4029-4038.
26. Milsted A, Underwood A, Dunmire J, et al. Regulation of multiple renin-angiotensin system genes by Sry. J Hypertens. 2010;28:59-64.
27. Sim H, Rimmer K, Kelly S, Ludbrook L, Clayton A, Harley V. Defective Calmodulin-Mediated Nuclear Transport of the Sex Determining Region of the Y Chromosome (SRY) in XY Sex Reversal. Mol Endocrinol. 2005;19:1884-1892. (Pubitemid 41007899)
28. Dubin R, Ostrer H. Sry is a transcriptional activator. Mol Biol. 1994;8:1182-1192. (Pubitemid 24292595)
29. Liu X, Chen X, Zachar V, Chang C, Ebbesen P. Transcriptional activation of human TR3/nur77 gene expression by human T-lymphotropic virus type I Tax protein through two AP-1-like elements. J Gen Virol. 1999;80:3073-3081.
30. Smith M, Cass W. Oxidative Stress and Dopamine Depletion In An Intrastriatal 6-Hydroxydopamine Model Of Parkinson's Disease. Neuroscience. 2007;144:1057-1066. (Pubitemid 46013981)
31. Blum D, Torch S, Lambeng N, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol. 2004;65:135-172. (Pubitemid 32524182)
32. Bernstein A, Garrison S, Zambetti G, O'Malley K. 6-OHDA generated ROS induces DNA damage and p53- and PUMA-dependent cell death. Mol Neurodegener. 2011;6:2.
33. Warr N, Carre G, Siggers P, et al. Gadd45γ and Map3k4 interactions regulate mouse testis determination via p38 MAPK-mediated control of Sry expression. Dev Cell. 2013;23:1020-1031.
34. Gierl MS, Gruhn WH, von Seggern A, Maltry N, Niehrs C. GADD45G functions in male sex determination by promoting p38 signaling and Sry expression. Dev Cell. 2012;23:1032-1042.
35. Tao Q, Fan XJ, Li T, Tang Y, Yang D, Le W. Gender Segregation in Gene Expression and Vulnerability to Oxidative Stress Induced Injury in Ventral Mesencephalic Cultures of Dopamine Neurons. J Neurosci Res. 2011;90:167-178.
36. Yuan X, Lu M, Li T, Balk S. SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem. 2001;276:46647-46654.
37. Pilon N, Daneau I, Paradis V, et al. Porcine SRY Promoter Is a Target for Steroidogenic Factor. Biol Reprod. 2003;68:1098-1106. (Pubitemid 36359096)
38. Saito Y, Nishio K, Ogawa Y, et al. Molecular mechanisms of 6-hydroxydopamine-induced cytotoxicity in PC12 cells: involvement of hydrogen peroxide-dependent and -independent action. Free Radic Biol Med. 2007;42:675-685. (Pubitemid 46205147)
39. Robbins J, Otsuka F, Tarone R, et al. Radiosensitivity in Alzheimer disease and Parkinson's disease. Lancet. 1983;321:468-469.
40. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munzo-Patino A, Labandeira-Garcia J. Autoxidation and Neurotoxicity of 6-Hydroxydopamine in the Presence of Some Antioxidants: Potential Implication in Relation to the Pathogenesis of Parkinson's Disease. J Neurochem. 2000;74:1605-1612. (Pubitemid 30163982)
41. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95:521-530. (Pubitemid 28533308)
42. Gomez-Lazaro M, Galindo M, Concannon C, et al. 6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J Neurochem. 2008;104:1599-1612. (Pubitemid 351316775)
43. Lu B, Yu H, Chow C, et al. GADD45gamma mediates the activation of the p38 and JNKMAP kinase pathways and cytokine production in effector TH1 cells. Immunity. 2001;14:583-590. (Pubitemid 32520869)
44. Ryu E, Angelastro J, Greene L. Analysis of gene expression changes in a cellular model of Parkinson disease. Neurobiol Dis. 2005;18:54-74. (Pubitemid 40092896)
45. Simunovic F, Yi M, Wang Y, Stephens R, Sonntag KC. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS One. 2010;5:e8856.
46. Damier P, Hirsch E, Agid Y, Graybiel A. The substantia nigra of the human brain. II. Patters of loss of dopamine-containing neurons in Parkinson's disease. Brain. 1999;122:1437-1448. (Pubitemid 29374122)
47. Yuan H, Chen R, Zhu Y, Peng C, Zhu X. The neuroprotective effect of overexpression of calbindin-D28k in an animal model of Parkinson's disease. Mol Neurobiol. 2013;47:117-122.
48. Fearnley J, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
49. Fujita Y, Izawa Y, Ali N, et al. Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:257-266. (Pubitemid 43123953)
50. Wooten G, Curre L, Bovbjerg V, Lee J, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry. 2004;75:637-639. (Pubitemid 38406668)
51. Tamas A, Lubics A, Szalontay L, Lengvari I, Reglodi D. Age and gender differences in behavioral and morphological outcome after 6-hydroxydopamine- induced lesion of the substantia nigra in rats. Behav Brain Res. 2005;158:221-229. (Pubitemid 40208468)
52. Murray H, Pillai A, McArthur S, et al. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience. 2003;116:213-222. (Pubitemid 36110447)
53. DeLisi L. Gender and age at onset of schizophrenia. Br J Psychiatry. 1997;170:234-240.
54. Su H, Lau Y. Identification of the transcriptional unit, structural organization, and promoter sequence of the human sex-determining region Y (SRY) gene, using a reverse genetic approach. Am J Hum Genet. 1993;51:24-38. (Pubitemid 23059045)